Aug 6 |
BioMarin pares Roctavian spending as it narrows sales focus
|
Aug 6 |
BioMarin Pharmaceutical Inc. (BMRN) Q2 2024 Earnings Call Transcript
|
Aug 5 |
BioMarin (BMRN) Reports Q2 Earnings: What Key Metrics Have to Say
|
Aug 5 |
BioMarin to focus Roctavian efforts on US, Germany, Italy
|
Aug 5 |
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
|
Aug 5 |
BioMarin raises 2024 guidance for revenue, non-GAAP EPS
|
Aug 5 |
BioMarin: Q2 Earnings Snapshot
|
Aug 5 |
BioMarin Pharmaceutical Non-GAAP EPS of $0.96 beats by $0.36, revenue of $712.03M beats by $49.76M
|
Aug 5 |
BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance
|
Aug 4 |
BioMarin Pharmaceutical Q2 2024 Earnings Preview
|